Rektron Group's Trading Arm - DL Hudson's Non-Bank Lender, Artis Finance, Enters Administration
VANCOUVER, BC / ACCESS Newswire / March 7, 2025 / Rektron Group Inc. (CSE:REK.U)(FRA:F75) ('Rektron' or the 'Company'), a global commodity trading group with subsidiaries that specialize in trading energy, metals, and energy transition commodities, announces that it is aware of recent reports regarding Artis Finance Ltd. ('Artis') having entered administration in the United Kingdom. The Company's trading arm DL Hudson Ltd. is a finance partner of Artis Loanco 1 Plc ('Artis Loanco 1"), Artis' subsidiary.
While Artis has entered administration, Artis Loanco 1 remains operational (Source: Trade Finance Global, March 6, 2025). The Company advises stakeholders that this development is not expected to have any material impact on the Company's financial position, operations, or commitments and ongoing trade activities remain stable and fully operational. Artis has provided DL Hudson funding support for select trading activities, however, DL Hudson operates with a diversified financial strategy and robust liquidity, ensuring business continuity remains unaffected.
The Company is closely monitoring the situation and remains committed to engaging with relevant stakeholders, to ensure a smooth transition. The Company remains focused on delivering value to its clients and partners while executing its strategic objectives with confidence.
About Rektron Group Inc.
The Company is the holding and parent company of Rektron AQ Limited, which is the holding and parent company of DL Hudson Limited. DL Hudson Limited is the trading arm of a group of companies, of which there are several subsidiaries that support the group's global commodity trading operations. The Company is headquartered in Vancouver, British Columbia, while Rektron AQ Limited is headquartered in London, UK.
The Company focuses on maintaining an experienced team of management and traders, extensive geographical and product diversification, trading and logistical expertise, and financial and risk management.
The team at the Group is composed of energy and metals traders, and finance professionals with expertise from the City of London and Wall Street. The trading expertise includes principal energy and metals products, particularly ferrous and nonferrous metals, recycled metals and Energy Transition Commodities ('ETC'), crude oil and Euro VI-compliant refined oil products. The Company and its affiliates transact across all compliant markets following the international trade regulations and guidelines. Please visit www.rektrongroup.com for further information.
Forward-Looking Statements
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, 'forward‐looking statements') that relate to Rektron's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as 'will likely result', 'are expected to', 'expects', 'will continue', 'is anticipated', 'anticipates', 'believes', 'estimated', 'intends', 'plans', 'forecast', 'projection', 'strategy', 'objective' and 'outlook') are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Rektron's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, other factors set forth under 'Caution Regarding Forward-Looking Statements' and 'Risk Factors' in the Company's amended and restated final prospectus dated August 12, 2024. Rektron undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Rektron to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
No securities regulatory authority has either approved or disapproved of the contents of this news release.
FOR FURTHER INFORMATION CONTACT:
Chris Santa Cruz
Alliance Advisors IR
604-787-0563
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Combined Shareholders' Meeting of June 19, 2025: All Submitted Resolutions Were Adopted
NEUILLY-SUR-SEINE, France--(BUSINESS WIRE)--The Combined Shareholders' Meeting of Bureau Veritas (the "Company"), chaired by Mr. Laurent Mignon, Chairman of the Board of directors, was held today at the Company's head office. All resolutions submitted to the Shareholders' Meeting were adopted at a large majority, including: The approval of the statutory and consolidated financial statements for the financial year ending on December 31, 2024, and the approval of a dividend distribution of €0.90 per share to be paid in cash on July 3, 2025 (ex-date on July 1, 2025) on positions closed on July 2, 2025; The approval of a related-party agreement concerning the Company's participation in Wendel's share placement (acquisition by the Company of its own shares); The approval of the report on Corporate Officers' compensation; The approval of fixed, variable and extraordinary components of the total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mr. Laurent Mignon, in his capacity as Chairman of the Board of Directors; The approval of fixed, variable and extraordinary components of total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mrs. Hinda Gharbi, in her capacity as Chief Executive Officer; The approval of the compensation policy for the Directors, the Chairman of the Board of Directors and the Chief Executive Officer for 2025; The authorization granted to the Board of Directors to trade in the Company's ordinary shares; The delegations and/or financial authorizations granted to the Board of Directors. The Shareholders' Meeting renewed the term of office as Director of Mr. Laurent Mignon, and the Board of Directors reappointed him as Chairman of the Board of Directors. The Shareholders' Meeting also renewed the terms of office as Directors of Ms. Julie Avrane, Ms. Ana Giros Calpe and Mr. Jérôme Michiels. Ms. Lucia Sinapi-Thomas is leaving the Board, as her term of office has expired. The Directors commended her contribution to the Board's discussions and decisions, as well as to the work of its Committees. To replace Ms. Sinapi-Thomas, the Shareholders' Meeting appointed Ms. Elodie Perthuisot as an independent director for a term of four years. Elodie Perthuisot is a member of the Carrefour Group's Executive Committee and currently heads Carrefour Spain, one of the group's main subsidiaries. Holding an engineering degree from the École Polytechnique, she began her career in the public sector - she notably headed the office of Frédéric Mitterrand, Minister of Culture and Communication - before joining the retail sector, leading the commercial management and multichannel transformation of Fnac and then Fnac Darty. She joined Carrefour in 2018 where she has successively led the marketing in France, e-commerce and, since 2021, the group's digital and technological transformation. Under her leadership, Carrefour has significantly accelerated its digital and data ambitions, becoming a company recognized for its progress in these areas. The Bureau Veritas Board of Directors will be able to rely on her diverse experience, and in particular on her expertise in digital transformation and operational management. In the activity reports, Mrs. Hinda Gharbi, Chief Executive Officer, and Mr. François Chabas, Chief Financial Officer, presented the 2024 highlights, the 2024 financial results, providing specific details on revenue, adjusted operating profit, net earnings per share, cash flow statement and the financial position. Mrs. Hinda Gharbi, Chief Executive Officer, then presented the review of the Group's activities for the 2024 financial year, and detailed the first quarter revenue as well as the 2025 outlook. She also provided an update on the LEAP I 2028 strategic plan. Mr. Laurent Mignon and Mr. Pascal Lebard, Lead Independent Director, respectively presented corporate governance and compensation components of the Directors, the Chairman of the Board of directors and the Chief Executive Officer in 2024, as well as the compensation policies. The broadcast of the Shareholders' Meeting, including the full presentation and the complete results of the vote of the resolutions, will be available on the Company's website ( ABOUT BUREAU VERITAS Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. Our information is certified with blockchain technology. Check that this press release is genuine at
Business Wire
12 hours ago
- Business Wire
RDDT Investors Have Opportunity to Lead Reddit, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reddit, Inc. ('Reddit' or 'the Company') (NYSE: RDDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 29, 2024 and May 20, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 18, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Reddit's traffic was negatively impacted by changes to Google's search algorithm and features like AI Overview. The Company's traffic was impacted in materially different ways than it had been by prior Google changes. The Company was aware that Google users added 'Reddit' to their search hoping to get a answer to their question without actually visiting Reddit. The Company failed to overcome the challenges caused by Google in the short term. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Reddit, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
14 hours ago
- Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Following the submission of the Marketing Authorization Application to the EMA for our lead asset, we are excited to advance Xervyteg® toward commercialization — a potential world first for a microbiota therapeutic in oncology. Share MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provides a business update and highlights its key milestones expected for the second half of 2025. 'Following the submission of the Marketing Authorization Application to the EMA for our lead asset, Xervyteg ®, earlier this month, we are excited to advance Xervyteg ® toward commercialization — a potential world first for a microbiota therapeutic in oncology — and are now fully focused on progressing registration activities across Europe', said Hervé Affagard, CEO and co-founder of MaaT Pharma. 'This marks a major step in confirming our commitment to address high unmet medical needs and, importantly, it serves as a stepping stone toward international expansion, as we aim to bring our therapies to patients worldwide" Pipeline highlights In Hemato-Oncology Acute Graft-versus-Host Disease (aGvHD) – Xervyteg ® (MaaT013) In January 2025, the Company announced positive topline results from the pivotal Phase 3 ARES Study evaluating Xervyteg ® (MaaT013) in aGvHD. The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of Xervyteg ® as third-line treatment of aGvHD with gastrointestinal involvement (GI-aGvHD) consistent with communicated Early Access Program results. On June 02, 2025, the Company announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under the registered brand name of Xervyteg ®. If approved, the Marketing Authorization would establish Xervyteg ® as the first microbiota therapeutic approved by the EMA, the first one in hemato-oncology worldwide and the first approved therapy in third-line GI-aGvHD. On June 13, 2025, the Company presented positive updated data in Early Access Program for 173 patients at the 2025 annual EHA Congress supporting the high efficacy and good safety profile of Xervyteg ®. This dataset confirms the breakthrough potential of Xervyteg ® for aGvHD patients with limited treatment options. Final results from the pivotal ARES study, including 12-month overall survival data, are expected before the end of 2025 and will be incorporated into the filing dossier. The potential marketing authorization could be delivered around mid-2026, enabling the start of the commercialization of Xervyteg ® in Europe. MaaT Pharma is advancing discussions with potential partners to accelerate the commercialization plan across Europe. MaaT Pharma primarily focuses on the commercialization of its most advanced asset with the completion of regulatory steps in Europe, and dedicated preparation activities for the European launch of Xervyteg ®. In parallel, the Company continues discussions with the FDA to optimize a dedicated pivotal study in the U.S., with the objective of enabling the earliest possible access to Xervyteg ® for U.S. patients. Such a study could be initiated in 2026 (instead of Q4 2025), subject to regulatory confirmation as MaaT Pharma continues watching the evolving regulatory policies and process in the United States. The Company continues the ongoing Early Access Program in the United States, initiated in December 2024. Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) - MaaT033 Over the past 12 months, three DSMB safety assessments were conducted for MaaT033 in the Phase 2b PHOEBUS randomized trial designed to be pivotal: two routine evaluations and one interim analysis focused on excess mortality. All confirmed a favorable safety profile and recommended continuation of the trial without modifications. The last patient enrollment in the trial is anticipated for mid-2026 while the 1-year OS results are expected in H2 2027. In Immuno-Oncology Xervyteg ® and MaaT033 – Proof-of-Concept trials using the MET-N platform (donor derived conducted as Investigator-Sponsored Trials (ISTs). In March 2024, the Company completed patient recruitment for the Phase 2a randomized clinical trial (NCT04988841) (PICASSO) sponsored by AP-HP in Paris and in collaboration with INRAE and Institut Gustave Roussy, evaluating Xervyteg ® in combination with immune checkpoint inhibitors (ICI), ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), in metastatic melanoma patients. The Company provided its Xervyteg ® drug candidate and placebo and contributes to the microbiome profiling of patients using its proprietary gutPrint ® AI research engine, while the trial investigator-sponsor handled recruitment, treatment and is overseeing data collection and analysis. Data readout is expected in H2 2025 as previously announced. In May 2024, the Company announced its participation in the IMMUNOLIFE 'RHU' (university hospital trial) program, a consortium including academic partners, such as Institut Gustave Roussy (IGR), a world-renowned center in the field of cancer treatment, and biotech companies. MaaT033 will be tested as a concomitant treatment to cemiplimab (Regeneron), an anti-PD1 therapy, to assess the potential increase in response rate in patients having received antibiotics. This investigator-sponsored, randomized, multicenter Phase 2 trial will evaluate MaaT033 in patients with advanced non-small cell lung cancer (NSCLC), with MaaT Pharma supplying the investigational product. The trial is expected by the sponsor to start mid-2025. MaaT034 – Next-generation drug candidates with co-cultured technology (MET-C platform) In April 2025, the Company presented new preclinical data for MaaT034, its next generation product, showing compelling anti-tumor efficacy results in germ-free mice at the American Association for Cancer Research (AACR) Annual Meeting 2025. Key results included: Metagenomic analysis shows that MaaT034 reproduces the microbial functions of Xervyteg ® MaaT034 improves DC-mediated T cell activation and potentiates anti-tumor effects mediated by anti-PD-1 checkpoint blockade in vitro. 70% of MaaT034 microbial species engraft in mice, ensuring an enduring presence of beneficial bacteria in the gut environment. MaaT034 increases the production of key microbial-derived metabolites such as short-chain fatty acids in germ-free mice. This translates into an improved gastrointestinal physiology as evidenced by gut mucosal restoration. MaaT034 optimizes anti-PD1 mediated activity in tumor-bearing, germ-free mice. While anti-PD1 alone reduced tumor growth by 10%, the combination of anti-PD1 and MaaT034 resulted in a 83.7% tumor growth reduction (compared to a 24.2% reduction when using a single strain of Akkermansia muciniphila bacteria). In Neurodegenerative Diseases In May 2025, MaaT Pharma announced positive final Phase 1b results for MaaT033 in Amyotrophic Lateral Sclerosis (ALS), showing a favorable safety and tolerability profile supported by biomarker and microbiome analyses. Moving forward, the Company is seeking a partner to further advance clinical evaluation in ALS. As a reminder, the Company's Annual General Meeting will take place on Friday, June 20, 2025, at 9:30am CET at the Company's headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live. A presentation by the management team on recent developments and perspectives will take place from 9:00 to 9:30 a.m. CET, prior to the General Meeting. For more information, please visit the investors section on the Company's website. --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
